IBRX Investors Have Chance to Lead Securities Fraud Case Against ImmunityBio, Inc.

Investors Encouraged to Join ImmunityBio Securities Fraud Lawsuit

In a significant turn of events, the Schall Law Firm, a prominent national litigation firm specializing in shareholder rights, has called attention to a potentially impactful class action lawsuit against ImmunityBio, Inc. The legal action targets alleged securities fraud under the Securities Exchange Act of 1934, particularly focusing on violations of §§10(b) and 20(a) and Rule 10b-5 as set out by the U.S. Securities and Exchange Commission (SEC).

The case pertains specifically to investors who acquired ImmunityBio’s securities during the period from January 19, 2026, to March 24, 2026. This period has been designated as the 'Class Period.' Investors affected are urged to contact the Schall Law Firm before the approaching deadline of May 26, 2026. By joining this action, they could potentially recoup some of the losses suffered under circumstances now believed to be deceptive.

The Nature of Allegations

The complaint asserts that ImmunityBio made various false and misleading representations regarding its product capabilities, particularly concerning the Anktiva drug. Allegedly, the company overstated the efficacy and potential of this therapeutic agent, leading investors to had a skewed perception of the company's prospects.

As news of these alleged inaccuracies disseminated across the market, stock prices likely plummeted, significantly impacting investor financial health. When the realities of the situation came to light, individuals and institutional investors who bought into the hype surrounding ImmunityBio faced considerable financial repercussions.

Attorney Contact Information

Potential class members are encouraged to liaise with Brian Schall, an attorney at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA. Those interested in seeking further information or clarifications regarding their rights in this case can reach out at 310-301-3335 or through the firm's official website at www.schallfirm.com. Alternatively, parties with interest can communicate via email at the designated firm address.

It’s important to note that the class in this lawsuit has not yet been certified, which means that by taking no action, potential participants could remain as absent class members without representation.

Implications for Investors

This situation markedly illustrates the heightened risks and vulnerabilities present in the stock market, especially concerning biotechnology firms like ImmunityBio. Investors who find themselves bewildered by complexities surrounding such drugs must remain vigilant, understanding that the information presented by a company can significantly affect stock performance.

The Schall Law Firm's specialization in securities class action lawsuits and shareholder rights litigation comes into play here, as they work diligently to protect investors and advocate for their rights in a system that can often be opaque and challenging.

Should you have experienced losses due to the events surrounding ImmunityBio between the outlined dates, it would be prudent to consider taking action by contacting the Schall Law Firm. Don't hesitate to secure your right to compensation as this case continues to unfold.

In conclusion, with the opportunity to join a class action lawsuit on the table, affected investors have a chance to reclaim their losses and challenge what they perceive to be wrongdoing on the part of ImmunityBio, Inc.